F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California in 1971, but conducted most of its operations in nearby Emeryville. Before merging with another company in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Leto Laboratories is a research team that is specialized in platform building for protein re-engineering. The company aims to fill the gaps in the treatment of cancer and rare diseases to benefit patients. Leto Labs has a diversified research team that specializes in platform development for novel protein re-engineering.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Technology) is located in the Beijing Economy-Technology Development Area (BDA), also well known as the "Pharmaceutical Valley". Based on biotechnology platforms, Kawin Technology is committed to become a public company that provides the best healthcare solutions to liver disease for our patients. Since establishment, Kawin Technology has formed strategic partnership with Legend Capital, Haitong Capital and Cybernaut respectively. Kawin Technology is a High & New Technology Enterprise certified by Beijing Municipal Science & Technology Commission. It has also been listed as one of Hundred Pilot Enterprises and Top 100 Most-promising Enterprises by Zhongguancun Technology Park (also know as China’s Silicon Valley).

Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Jiangsu Jingsen Biomedical New Material Technology Co., Ltd., established on 2010-06-13, Business scope includes biomedical new materials and products,medical supplies,hygiene products,cosmetic,food research and development,technology transfer,Technical Consulting and Technical Services;Biological reagents for scientific research(medicine,Hazardous chemicals excluded)R & D and sales;food business(Subject to the items listed in the food business license);biochemical products(medicine,Hazardous chemicals excluded),medical instruments(limit<Medical Device Business License>Approved scope),hygiene products,sales of cosmetics;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:food production;Cosmetic production;Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Manufacturing of bio-based materials;Sales of bio-based materials;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Ningbo Borui Handa Biotechnology Co., Ltd., established on 2019-05-05, Business scope includes research and development of biotechnology,consult,transfer;Medical technology research and development;Chemical raw materials and products,laboratory consumables,Daily necessities,Equipment,Class II medical device,Instrumentation,Packaging Materials,Wholesale of cosmetics,retail;Enterprise management information,economic information,Travel Information,trade information,Business Consulting;marketing planning,account Serive,Exhibition display service,graphic design;Self-operated or agent import and export of goods and technologies,Except for goods and technologies that are restricted or prohibited from being imported or exported by the state.

Qichensheng Biotechnology (Zhuhai) Co., Ltd., established on 2018-08-30, The scope of business includes engaging in biomedicine,Development of biological detection and therapeutic technologies,production and sales,Technical Services,technical consulting,technology transfer,Technical Training;Sales of chemical products,chemical reagent,Instrumentation,Iclass of medical devices;Import and export of goods or technology;market survey,information service,Software development and sales,Information Security Services,System Integration and Installation;science communication,publication retail;Conference Services;Undertake exhibition and display activities.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. engages in the development and manufacture of biopharmaceutical focused on antibody drugs. It provides clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. Its products include yisaipu and jiannipai. The company was founded on January 25, 2002 and is headquartered in Shanghai, China.

Tianjin Linda Biotechnology Co., Ltd., established on 2010-05-19, The business scope includes biogenetic drugs,Vaccine Technology Development,Transfer and technical services;biological reagent,skin care products,Technical development and sales of health products.The country has a franchise,The special provisions shall be handled according to the special provisions of the franchise.

Tianjin Puying Biotechnology Co., Ltd., established on 2004-04-13, The business scope includes biogenetic drugs,vaccine,cosmetic,Technology development of health products,transfer;cosmetic,Skin care sales;Bioreagent technology development,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Beijing Meifuyuan Biomedical Technology Co., Ltd., established on 2009-02-27, Business scope includes technology development,technology transfer,technical consulting,Technology Promotion,Technical Services.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

SyntheX created a novel cell-based, synthetic biology-driven drug selection platform, that allows for the efficient synthesis and identification of peptides and macrocycles that selectively disrupt intracellular protein-protein interactions of interest. Although the platform has broad application, the initial focus is on oncology. Targets are selected based on the concepts of synthetic lethality and oncogene addiction, with the first program focused on DNA damage repair and working through a novel cell death mechanism that was uncovered.

FortuneRock (China) Ltd., a privately held biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 wholly owned subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with high clinical value for the treatment of life-threatening and debilitating diseases. Currently, the company has one drug in clinical Phase I, one in clinical Phase II, another waiting for approval to enter into clinical Phase I, and several novel drugs in pre-clinical studies, all for different indications.